Ryvu Therapeutics S.A.
RVU.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | PLN 1 | PLN 1 | PLN 1 | PLN 1 |
| - Cash | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| + Debt | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Enterprise Value | PLN 1 | PLN 1 | PLN 1 | PLN 1 |
| Revenue | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| % Growth | 66.4% | 20.8% | 246.9% | – |
| Gross Profit | PLN 0 | PLN 0 | PLN 0 | -PLN 0 |
| % Margin | 74.9% | 62.5% | 55.1% | -22.7% |
| EBITDA | -PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |
| % Margin | -124.2% | -172.9% | -168% | -589.6% |
| Net Income | -PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |
| % Margin | -142.9% | -196.6% | -215.9% | -706.9% |
| EPS Diluted | -4.82 | -4.02 | -4.57 | -4.31 |
| % Growth | -19.9% | 12% | -6% | – |
| Operating Cash Flow | -PLN 0 | -PLN 0 | PLN 0 | -PLN 0 |
| Capital Expenditures | -PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |
| Free Cash Flow | -PLN 0 | -PLN 0 | PLN 0 | -PLN 0 |